8-Bromo cyclic guanosine monophosphate mimics the actions of nitroglycerin on alpha-adrenergic mechanisms in canine saphenous vein.
The purpose of the present study was to determine if 8-bromo cyclic guanosine monophosphate (cGMP) mimics the actions of nitroglycerin in inhibiting alpha 1- versus alpha 2-mediated constrictor responses in vitro using rings prepared from isolated canine saphenous vein. Contractions were produced by phenylephrine, a selective alpha 1-adrenoceptor agonist and B-HT 920, a selective alpha 2-adrenoceptor agonist. The inhibitory effects of nitroglycerin and 8-bromo cGMP on contractions produced by submaximal concentrations (EC75) of phenylephrine and B-HT 920 were determined. 8-Bromo cGMP like nitroglycerin produced a selective antagonism of alpha 2-adrenoceptor-mediated responses and had minimal effects on alpha 1-adrenoceptor-induced constriction. However, after removal of spare postsynaptic vascular alpha 1-adrenoceptors by treatment with the irreversible alpha-adrenoceptor antagonist phenoxybenzamine (5 X 10(-8) M, 1 X 10(-7) M), the alpha 1-adrenoceptor-mediated vasoconstrictor responses of phenylephrine became highly sensitive to antagonism by 8-bromo cGMP and nitroglycerin. These data suggest that the action of 8-bromo cGMP like nitroglycerin is 'buffered' by the presence of a large alpha 1-adrenoceptor reserve in canine saphenous vein. The similarity in the efficacy and potency of these two agents suggests that the effects of nitroglycerin in canine saphenous vein may be the result of an increase in intracellular cGMP.
Eskinder
H
H
Gross
G J
GJ
D000818:Animals; D001381:Azepines / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D005996:Nitroglycerin / Q000494:pharmacology*; D009599:Nitroprusside / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D012501:Saphenous Vein / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects*
D001381:Azepines; D011942:Receptors, Adrenergic, alpha; D009599:Nitroprusside; D010656:Phenylephrine; C016276:8-bromocyclic GMP; C024763:talipexole; D005996:Nitroglycerin; D006152:Cyclic GMP; D002118:Calcium